Cerevance Media Center

Current News

December 4, 2019

Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s Disease

Cerevance, announced today the initiation of a Phase 2 clinical trial of CVN424, an oral, first-in-class compound that selectively modulates a novel, non-dopaminergic target selectively expressed in an important class of neurons in the striatum.

READ FULL

June 3, 2019

Cerevance Appoints CNS Drug Developer James Summers, Ph.D. as Scientific Advisor

Cerevance has appointed pharmaceutical industry veteran, James Summers, Ph.D., as a key scientific advisor to guide the company in its drug discovery and development efforts.  Dr. Summers brings extensive experience in the discovery of...

READ FULL

April 30, 2019

Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424

Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has successfully completed its Phase 1 clinical trial of CVN424, the company’s first-in-class, orally-delivered compound in development for the treatment of Parkinson’s disease.

READ FULL

April 16, 2019

Cerevance Appoints Industry Veteran Roland Bürli, Ph.D. as Vice President of Drug Discovery

Roland Bürli, Ph.D. as Vice President of Drug Discovery brings expertise in preclinical drug discovery, specializing in medicinal and synthetic chemistry, with a proven track record from hit identification through lead optimization, having led efforts that discovered six pre-clinical candidate molecules, including a program now in Phase II.

READ FULL

News Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

February 22, 2024

Cerevance to Participate at the TD Cowen 44th Annual Health Care Conference

Date:
Monday, March 4, 2024
Time:
Scheduled Meetings
Location:
Boston, MA
Media:
Scheduled Meetings
Read full

December 5, 2023

Cerevance to Participate in Fireside Chat at the 2023 RBC Capital Markets Healthcare Private Company Virtual Conference

Date:
Thursday, December 14, 2023
Time:
1:10 – 1:40 pm ET
Location:
Virtual
Media:
Fireside Chat
Read full

November 28, 2023

Cerevance Announces Presentation at the 34th International Symposium on ALS/MND

Date:
Thursday, December 7, 2023
Time:
5:45 – 7:45pm CET
Location:
Basel, Switzerland
Media:
Poster
Read full

Events Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

June 27, 2024

CryoEM Structure of the human THIK-1 K2P K+ Channel Reveals a Lower ‘Y-gate’ Regulated by Lipids and Anaesthetics

Rödström, K. E.J., Eymsh, B., Proks, P., Hayre, M. S., Madry, C., Rowland, A., Newstead, S., Baukrowitz, T., Schewe, M., Tucker, S. J.

Viewview

January 26, 2023

Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor

Mu, C., Li, X., Yang, Y., Zhou, Y., Wang, C., Doyle, K.J., Ye, N., Mistry, A., Burli, R.

Viewview

December 1, 2020

First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate

Sun, H., Monenschein, H., Schiffer, H.H., Reichard, H.A., Kikuchi, S., Hopkins, M., Macklin, T.K., Hitchcock, S., Adams, M., Green, J., Brown, J., Murphy, S.T., Kaushal, N., Collia, D.R., Moore, S., Ray, W.J., English, N.M., Carlton, M.B, Brice, N.L.

Viewview

February 26, 2024

Differential Contribution of THIK‑1 K+ Channels and P2X7 Receptors to ATP‑Mediated Neuroinflammation by Human Microglia

Rifat, A., Ossola, B., Bürli, R. W. , Dawson, L. A., Brice, N. L., Rowland, A., Lizio, M., Xu, X., Page, K., Fidzinski, P., Onken, J., Holtkamp, M., Heppner, F. L., Geiger, J. R. P., Madry, C.

Viewview

March 21, 2022

The Two Pore Potassium Channel THIK-1 Regulates NLRP3 Inflammasome Activation

Drinkall, S., Lawrence, C.B., Ossola, B., Russell, S., Bender, C., Brice, N.L., Dawson, L.A., Harte, M., Brough D.

Viewview

November 21, 2022

Pharmacological Targeting of Glutamatergic Neurons within the Brainstem for Weight Reduction

Schneeberger, M., Brice, N.L., Pellegrino, K., Parolar, L., Shaked, J.T., Page, K., Marchildon, F., Barrows, D., Carroll, T.S., Tolpiko, T., Mulligan, V., Barker, D., Glen, A., Newman, R., Ortuño, M.J., Renier, N., Nectow, A.R., Cohen, P., Carlton, M., Heintz, N., Friedman, J.M.

Viewview